The ICAR-Central Institute of Brackishwater Aquaculture (ICAR-CIBA) has partnered with Neomeds to transfer the ‘CIBA EHP Cura I’ technology, a new treatment for shrimp disease. This new solution addresses the global threat of Enterocytozoon hepatopenaei (EHP), a microsporidian pathogen that poses a serious threat to the shrimp industry.

A Six-Year Research Effort Yields Fruit

After six to seven years of research, ICAR-CIBA successfully developed ‘CIBA EHP Cura I’, a treatment that underwent rigorous field validation before being commercialized.

The partnership between ICAR-CIBA and Neomeds marks a significant step towards expanding the reach and impact of this technology. According to Dr. Kuldeep K. Lal, Director of ICAR-CIBA, combating the EHP pathogen is critical for the shrimp industry, and ‘CIBA EHP Cura I’ is a vital tool in mitigating this challenge. The treatment has the potential to revolutionize shrimp farming practices, making them more sustainable and resilient against disease outbreaks.